Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
Wyeth Study Finds Two Recombinant Factor VIII Products Equivalent
 

Wyeth Pharmaceuticals announced the results of a study demonstrating the comparability
of its recombinant factor VIII (rFVIII) drug, ReFacto®, with another rFVIII product, Baxter's Advate®. Both products are indicated for the prevention and control of bleeding episodes associated with hemophilia A.

The study examined the pharmacokinetics (the interaction between the body and a drug) of both products in 17 patients at eight sites. The participants were all previously treated patients. They first underwent a three day "washout period" during which they received no treatment. After that, each patient was randomly selected to receive a single infusion of either ReFacto® or Advate®. Following a second washout period, patients were treated with the alternate product. Results yielded from blood samples taken before and after the infusions showed that the products are bioequivalent--therapeutically comparable and with a similar clinical effect on the body.   

"Due to the limited number of studies comparing products, healthcare professionals and patients often rely on anecdotal reports to gather information on clotting factor products. This study provides 'real-world' data that will help us to make more informed decisions," said Jorge Di Paola, MD, Assistant Professor of Pediatrics and Director of the Hemophilia Treatment Center at the University of Iowa.

Source: Wyeth news release dated May 23, 2006